Thomas Denize

14PUBLICATIONS
99CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.

|Jul 02, 2025
Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma.

Chris Labaki, Eddy Saad, Katrine N Madsen

|Feb 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.

Miya B Hugaboom, Lena V Wirth, Kelly Street

|Dec 07, 2023
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients.

Thomas Denize, Opeyemi A Jegede, Sayed Matar

|Aug 30, 2023
Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma.

Thomas Denize, Catherine B Meador, Anna B Rider

|Jun 06, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.

Renee Maria Saliby, Talal El Zarif, Ziad Bakouny

Pageof 3

Frequent Collaborators

9 joint publications

Sabina Signoretti

7 joint publications

David Braun

6 joint publications

Toni K Choueiri

6 joint publications

David F McDermott